Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Linda M. Murphy"'
Autor:
Daniel W. Visscher, Derek C. Radisky, Keith L. Knutson, Celine M. Vachon, Lori A. Denison, Erin E. Miller, Linda M. Murphy, Melody L. Stallings-Mann, Jodi M. Carter, Alvaro Pena, Rushin A. Brahmbhatt, Stacey J. Winham, Marlene H. Frost, Muhammad Arshad, Tanya L. Hoskin, Amy C. Degnim
Purpose: Little is known about the role of the immune system in the earliest stages of breast carcinogenesis. We studied quantitative differences in immune cell types between breast tissues from normal donors and those from women with benign breast d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0097e7b5dabf0b9b3e34109432b196f6
https://doi.org/10.1158/1078-0432.c.6526565
https://doi.org/10.1158/1078-0432.c.6526565
Autor:
Daniel W. Visscher, Derek C. Radisky, Keith L. Knutson, Celine M. Vachon, Lori A. Denison, Erin E. Miller, Linda M. Murphy, Melody L. Stallings-Mann, Jodi M. Carter, Alvaro Pena, Rushin A. Brahmbhatt, Stacey J. Winham, Marlene H. Frost, Muhammad Arshad, Tanya L. Hoskin, Amy C. Degnim
Distribution of immune cell densities per sample presented as a five-number summary including the minimum (Min), 25th percentile (Q25), median (Q50), 75th percentile (Q75), and maximum (Max).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0129ad0ac4bdb4e7b24200a9cf0f0f10
https://doi.org/10.1158/1078-0432.22467188
https://doi.org/10.1158/1078-0432.22467188
Autor:
Yingwen Hu, Daniel W. Visscher, Jiayin Shen, Linda M. Murphy, Sunil Singhal, Karson S. Putt, Haiyong Han, Philip S. Low
Publikováno v:
Oncotarget
A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers. Because the therapeutic efficacy of these drugs depends prominently on the level of FR-
Autor:
Stacey J. Winham, Rushin D. Brahmbhatt, Derek C. Radisky, Lori A. Denison, Amy C. Degnim, Jodi M. Carter, Linda M. Murphy, Muhammad Arshad, Keith L. Knutson, Tanya L. Hoskin, Marlene H. Frost, Alvaro Pena, Melody Stallings-Mann, Daniel Kerekes, Daniel W. Visscher
Publikováno v:
Breast Cancer Research and Treatment
Purpose While the role of natural killer (NK) cells in breast cancer therapy has been investigated, little information is known about NK cell function and presence in nonmalignant and premalignant breast tissue. Here, we investigate and quantify NK c
Autor:
Erin Miller, Daniel W. Visscher, Derek C. Radisky, Muhammad Arshad, Amy C. Degnim, Jodi M. Carter, Keith L. Knutson, Lori A. Denison, Tanya L. Hoskin, Stacey J. Winham, Linda M. Murphy, Rushin A. Brahmbhatt, Alvaro Pena, Melody Stallings-Mann, Marlene H. Frost, Celine M. Vachon
Publikováno v:
Clinical Cancer Research. 23:3945-3952
Purpose: Little is known about the role of the immune system in the earliest stages of breast carcinogenesis. We studied quantitative differences in immune cell types between breast tissues from normal donors and those from women with benign breast d
Autor:
Stewart A. Low, Bingbing Wang, Eric L. Matteson, Philip S. Low, Karson S. Putt, Clemens Ruppert, Yingwen Hu, Jiayin Shen, Hans W.M. Niessen, Cheryl Nickerson-Nutter, Dimiter S. Dimitrov, Gerrit Jansen, Linda M. Murphy, Stephen J. Oliver, Yang Feng
Publikováno v:
Arthritis Research and Therapy, 21(1):143. BioMed Central
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-14 (2019)
Arthritis Research & Therapy
Hu, Y, Wang, B, Shen, J, Low, S A, Putt, K S, Niessen, H W M, Matteson, E L, Murphy, L, Ruppert, C, Jansen, G, Oliver, S J, Feng, Y, Dimitrov, D S, Nickerson-Nutter, C & Low, P S 2019, ' Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis ', Arthritis Research and Therapy, vol. 21, no. 1, 143 . https://doi.org/10.1186/s13075-019-1912-0
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-14 (2019)
Arthritis Research & Therapy
Hu, Y, Wang, B, Shen, J, Low, S A, Putt, K S, Niessen, H W M, Matteson, E L, Murphy, L, Ruppert, C, Jansen, G, Oliver, S J, Feng, Y, Dimitrov, D S, Nickerson-Nutter, C & Low, P S 2019, ' Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis ', Arthritis Research and Therapy, vol. 21, no. 1, 143 . https://doi.org/10.1186/s13075-019-1912-0
Objectives Most therapies for autoimmune and inflammatory diseases either neutralize or suppress production of inflammatory cytokines produced by activated macrophages (e.g., TNFα, IL-1, IL-6, IL-17, GM-CSF). However, no approved therapies directly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f86fea1408cd68a951029848818adc44
https://research.vumc.nl/en/publications/933709e3-08d8-4dcf-9eaa-7b43c4769024
https://research.vumc.nl/en/publications/933709e3-08d8-4dcf-9eaa-7b43c4769024
Publikováno v:
Archives of Pathology & Laboratory Medicine. 137:241-244
Context.— Lung cancer is the number one cause of cancer deaths in the United States and globally. The advent of targeted therapies has offered a new treatment paradigm for lung cancer, but currently validated and emerging drugs are effective in onl
Autor:
James F. Naughton, Nikki Parker, Lindsey M. Fourez, Ryan Rothenbuhler, Linda M. Murphy, Joseph A. Reddy, Liang Cheng, Christopher P. Leamon, Jane C. Stewart, José A. Ramos-Vara, Iontcho Radoslavov Vlahov, Philip S. Low, Michael O. Koch, Patrick J. Klein, Deborah W. Knapp, Deepika Dhawan
Publikováno v:
Cancer Research. 73:875-884
Folate receptors (FR) may be of use for targeted delivery of cytotoxic drugs in invasive urothelial carcinoma (iUC), for which improved therapy is needed. FR expression and function in iUC were explored and the antitumor activity and toxicity of a fo
Autor:
Thomas Harding, Scott H. Kaufmann, Elizabeth M. Swisher, Rachel M. Hurley, Kevin K. Lin, Mitch Raponi, Andrea E. Wahner Hendrickson, Jill M. Wagner, Daniel W. Visscher, Linda M. Murphy, Heidi Giordano, Iain A. McNeish
Publikováno v:
Cancer Research. 77:4676-4676
Background: PARP inhibitors (PARPis) are active in cancers with homologous recombination (HR) defects. Preclinical studies have shown that secondary mutations or alterations in gene expression (e.g., downregulation of 53BP1, Ku70, Ku80 or DNA-PKcs) r
Autor:
Chunling Hu, Schuyler O. Sanderson, Dalbir S. Sandhu, Chunrong Yu, Lewis R. Roberts, Alex A. Adjei, Ileana Aderca, Linda M. Murphy, Catherine D. Moser, Jinping Lai, Abdirashid M. Shire
Publikováno v:
Liver International. 30:1522-1528
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide (1). Because of frequent de novo and acquired resistance of HCCs to chemotherapy, there are limited options for therapy of HCC (2, 3). There is therefore an urgent ne